Advertisement
Screener

RAFAEL HOLDINGS, INC. (RFL) Income (Loss) from Equity Method Investments

2.0 / 5 stars · 27/66 Roast Me

RAFAEL HOLDINGS, INC. Income (Loss) from Equity Method Investments

RAFAEL HOLDINGS, INC. (RFL) reported Income (Loss) from Equity Method Investments of -$1.63 million for the 12-month period ending 2024-07-31, per its 10-K filed 2025-10-29.

Financial Statements › Income Statement › Other Income

us-gaap:IncomeLossFromEquityMethodInvestments · last filed 2025-10-29

  • RAFAEL HOLDINGS, INC. income (loss) from equity method investments for the quarter ending 2024-07-31 was $0.00.
  • RAFAEL HOLDINGS, INC. income (loss) from equity method investments for the quarter ending 2024-04-30 was $0.00.
  • RAFAEL HOLDINGS, INC. income (loss) from equity method investments for the quarter ending 2024-01-31 was -$1.63M.
  • RAFAEL HOLDINGS, INC. income (loss) from equity method investments for the quarter ending 2022-07-31 was $0.00, a 100.00% decline year-over-year.
  • RAFAEL HOLDINGS, INC. income (loss) from equity method investments for fiscal 2024 was -$1.63M.
  • RAFAEL HOLDINGS, INC. income (loss) from equity method investments for fiscal 2022 was -$575.00K, a 250.13% decline from fiscal 2021.
  • RAFAEL HOLDINGS, INC. income (loss) from equity method investments for fiscal 2021 was $383.00K, a 99.48% increase from fiscal 2020.
  • RAFAEL HOLDINGS, INC. income (loss) from equity method investments for fiscal 2020 was $192.00K.
Period endIncome (Loss) from Equity Method Investments 0 monthIncome (Loss) from Equity Method Investments 3 monthIncome (Loss) from Equity Method Investments 6 monthIncome (Loss) from Equity Method Investments 6 month as first filedIncome (Loss) from Equity Method Investments 9 monthIncome (Loss) from Equity Method Investments 12 month
2024-07-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-29
$0.00
derived: sum of 2 quarters · filed 2025-10-29
-$1.63M
derived: sum of 3 quarters · filed 2025-10-29
-$1.63M
10-K · filed 2025-10-29
2024-04-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-06-11
-$1.63M
derived: sum of 2 quarters · filed 2025-06-11
-$1.63M
10-Q · filed 2025-06-11
2024-01-31-$1.63M
10-Q · filed 2025-03-14
-$1.63M
10-Q · filed 2025-03-14
2022-07-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31
$0.00
derived: sum of 2 quarters · filed 2023-06-13
$0.00
derived: sum of 3 quarters · filed 2023-06-13
-$575.00K
10-K · filed 2022-10-31
2022-04-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-06-13
$0.00
derived: sum of 2 quarters · filed 2023-06-13
-$575.00K
10-Q · filed 2023-06-13
-$480.00K
derived: sum of 4 quarters · filed 2023-06-13
2022-01-31$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-03-14
-$575.00K
10-Q · filed 2023-03-14
-$480.00K
derived: sum of 3 quarters · filed 2023-03-14
-$384.00K
derived: sum of 4 quarters · filed 2023-03-14
2021-10-31-$575.00K
10-Q · filed 2022-12-13
-$480.00K
derived: sum of 2 quarters · filed 2022-12-13
-$384.00K
derived: sum of 3 quarters · filed 2022-12-13
-$288.00K
derived: sum of 4 quarters · filed 2022-12-13
2021-07-31$95.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31
$191.00K
derived: sum of 2 quarters · filed 2022-10-31
$287.00K
derived: sum of 3 quarters · filed 2022-10-31
$383.00K
10-K · filed 2022-10-31
2021-04-30$96.00K
10-Q · filed 2022-06-14
$192.00K
derived: sum of 2 quarters · filed 2022-06-14
$288.00K
10-Q · filed 2022-06-14
$427.00K
derived: sum of 4 quarters · filed 2022-06-14
2021-01-31$96.00K
10-Q · filed 2022-03-17
$192.00K
10-Q · filed 2022-03-17
$331.00K
derived: sum of 3 quarters · filed 2022-03-17
$384.00K
derived: sum of 4 quarters · filed 2022-03-17
2020-10-31$96.00K
10-Q/A · filed 2022-02-28
$235.00K
derived: sum of 2 quarters · filed 2022-02-28
$288.00K
derived: sum of 3 quarters · filed 2022-02-28
2020-07-31$139.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-10-18
$192.00K
derived: sum of 2 quarters · filed 2021-10-18
$192.00K
10-K · filed 2021-10-18
2020-04-30$53.00K
10-Q · filed 2021-06-14
$53.00K
10-Q · filed 2021-06-14
2019-01-31$103.00K
10-Q · filed 2020-03-05
$330.00K
10-Q · filed 2020-03-05
$93.00K
derived: sum of 3 quarters · filed 2020-03-05
$96.00K
derived: sum of 4 quarters · filed 2020-03-05
2018-10-31-$10.00K
10-Q · filed 2019-12-09
-$10.00K
derived: sum of 2 quarters · filed 2019-12-09
-$7.00K
derived: sum of 3 quarters · filed 2019-12-09
-$10.00K
derived: sum of 4 quarters · filed 2019-12-09
2018-07-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2019-10-04
$3.00K
derived: sum of 2 quarters · filed 2019-10-04
$0.00
derived: sum of 3 quarters · filed 2019-10-04
-$104.00K
10-K · filed 2019-10-04
2018-04-30$3.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-06-05
$0.00
derived: sum of 2 quarters · filed 2019-06-05
-$104.00K
10-Q · filed 2019-06-05
2018-01-31-$3.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-03-12
-$107.00K
10-Q · filed 2019-03-12
-$439.00K
10-Q · filed 2018-03-12
2017-11-16-$252.00K
10-Q · filed 2018-03-12
2017-10-31-$104.00K
10-Q · filed 2018-12-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aditxt, Inc. (ADTX)United States$0.000B
CDT Equity Inc. (CDT)United States$0.000B-0.01
Protagenic Therapeutics, Inc.\new (PTIX)United States$0.001B
Decoy Therapeutics Inc. (DCOY)United States$0.002B-0.27
Nexentis Technologies Inc. (NXTS)$0.002B
ORAGENICS INC (OGEN)United States$0.002B
JUPITER NEUROSCIENCES, INC. (JUNS)United States$0.002B-0.02
BioXcel Therapeutics, Inc. (BTAI)United States$0.002B
ZyVersa Therapeutics, Inc. (ZVSA)United States$0.002B
Matinas BioPharma Holdings, Inc. (MTNB)United States$0.003B